Vinci Partners Inv

Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.

PriceSmart

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ORIC

PSMT

ROKU

URGN

VINP

PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

AVNW

BAER

CLDI

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DTIL

EWCZ

IGMS

INTZ

MVST

Penguin Solutions, Inc. - Ordinary Shares

PENG

SENS

SILO

STAI

VMAR

XXII

ZCAR

Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

ADSE

ANGO

ATXS

BASE

HEAR

JFIN

LMNR

PAHC

Limoneira And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Vinci Partners Investments Ltd. - Class A Common Shares

Vinci Partners Investments Ltd

Deutsche Bank analyst Stephen Powers maintains Primo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMB#NYSE">PRMB</a>) with a Buy and raises the price target from $38 to $40.

Price Target

Analyst Ratings

PRMB

Deutsche Bank Maintains Buy on Primo Brands, Raises Price Target to $40

WIIM

AES shares are trading higher following a Q4 EPS beat.

Needham analyst Ryan MacDonald maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Buy and raises the price target from $385 to $400.

DUOL

Needham Maintains Buy on Duolingo, Raises Price Target to $400

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $325 to $340.

ADSK

Rosenblatt Maintains Buy on Autodesk, Raises Price Target to $340

PRAX

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Deutsche Bank analyst Steve Powers maintains Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) with a Buy and raises the price target from $60 to $61.

MNST

Deutsche Bank Maintains Buy on Monster Beverage, Raises Price Target to $61

Needham analyst Chris Pierce maintains Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and raises the price target from $11 to $13.

ACHR

Needham Maintains Buy on Archer Aviation, Raises Price Target to $13

On Friday,&nbsp;Amneal Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>)&nbsp;reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.15</a>.
The company reported sales of $730.52 million, up 18% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44037074/amneal-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $707.6 million</a>.
The increase was driven by Affordable Medicines (previously Generics) revenues growing 21% due to new product launches, biosimilars, and multiple other complex products, AvKARE revenues growing 14% due to new product launches, and Specialty revenues growing 16% driven by key branded products including CREXONT.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43921655/generic-drug-maker-amneal-pharmaceuticals-is-positioned-to-growth-well-ahead-of-peers-analyst-upgrades-stock" rel="noreferrer noopener">Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock</a>
It clocked a net loss of $31 million compared to a net loss of $99 million a year ago. Adjusted EBITDA&nbsp;in the fourth quarter of 2024 was $155 million, an increase of 9% compared to the fourth quarter of 2023, primarily due to strong revenue growth partially offset by higher spending in research and development and commercial initiatives to drive future growth.
Guidance: Amneal expects 2025 revenues of $3 billion—$3.1 billion and adjusted EPS of $0.65-$0.70 versus the consensus of $2.9 billion and $0.71, respectively.
"In 2025 and beyond, we are entering a new phase of growth by further expanding in high-growth areas such as Specialty, Biosimilars, and GLP-1 therapies. As a growing and diversified biopharmaceutical company, Amneal is well positioned to deliver substantial value creation for all our stakeholders," said Chirag and Chintu Patel, Co-Chief Executive Officers.
The company expects 2025 adjusted EBITDA of $650 million—$675 million, operating cash flow&nbsp;of $255 million—$285 million and capital expenditures of approximately $100 million.
Price Action: At the time of this writing, Friday, AMRX stock was up 1.43% at $8.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/44006332/nvidia-faces-new-ai-chip-challenge-as-huawei-gains-ground-in-china-despite-us-sanctions" target="_blank" rel="noreferrer noopener">Nvidia Faces New AI Chip Challenge As Huawei Gains Ground In China Despite US Sanctions</a></li>
</ul>

Earnings

Guidance

Health Care

General

AMRX

Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars

Upon closing of the transaction, the combined company will be renamed "BridgeBio Oncology Therapeutics, Inc." The combined company's common stock is expected to be listed on Nasdaq under the ticker symbol BBOT.
In addition to approximately $196 million held in Helix Acquisition Corp. II's trust account (assumed as of the closing and assuming no redemptions by Helix's public shareholders), the transaction also includes commitments for an approximately $260 million PIPE from a group of premier institutional investors.&nbsp;

HLXB

BridgeBio Oncology Therapeutics, Helix Acquisition Corp. II Enter Business Combination Agreement

Barrington Research analyst Alexander Paris maintains Carriage Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSV#NYSE">CSV</a>) with a Outperform and maintains $50 price target.

Barrington Research Maintains Outperform on Carriage Servs, Maintains $50 Price Target

HC Wainwright &amp; Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Buy and raises the price target from $66 to $72.

MIRM

HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $72

Deutsche Bank analyst Faiza Alwy initiates coverage on CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) with a Buy rating and announces Price Target of $89.

Initiation

CSGP

Deutsche Bank Initiates Coverage On CoStar Group with Buy Rating, Announces Price Target of $89

Craig-Hallum analyst Chase Knickerbocker initiates coverage on MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy rating and announces Price Target of $39.

MDWD

Craig-Hallum Initiates Coverage On MediWound with Buy Rating, Announces Price Target of $39

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) commenced its spring hiring season with 3,000 internship openings spanning multiple business units, half of which were <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">in artificial intelligence</a>.
Nearly half of the roles, including more than 80% of positions in the cloud computing arm, are AI-focused, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3300497/alibaba-begins-spring-hiring-3000-internship-roles-focused-ai" rel="noreferrer noopener">reports</a>.
Alibaba was among the first major global tech companies to open-source its large-scale AI models.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43884588/alibaba-leads-china-stock-rally-as-deepseeks-ai-breakthrough-and-xis-support-boost-investor-confidence" rel="noreferrer noopener">US Listed China Stocks Rally: Alibaba&#8217;s Performance, President Xi&#8217;s Support, DeepSeek AI Boost Investor Confidence</a>
Alibaba&#8217;s move coincided with DeepSeek&#8217;s <a target="_blank" href="https://www.benzinga.com/25/02/43970279/alibaba-and-deepseek-intensify-ai-showdown-challenging-openai-and-nvidias-market-dominance" rel="noreferrer noopener">AI model price war</a>, offering discounted off-peak pricing for developers. Chinese tech companies like&nbsp;Alibaba and its rivals were already&nbsp;engaged in a price war&nbsp;to win market share.&nbsp;
The first phase of the intern recruitment will focus on Alibaba Group, Alibaba Cloud and its AI-model research unit&nbsp;Tongyi Lab, food delivery service&nbsp;Ele.me, online mapping service and ride-hailing platform&nbsp;Amap, and video-gaming subsidiary&nbsp;Lingxi.
The next stage will cover the Taobao and Tmall Group e-commerce units, the Alibaba International Digital Commerce Group, and logistics service provider&nbsp;Cainiao.
Alibaba announced on Monday that it plans to invest at least $52.2 billion in AI and cloud computing infrastructure over the next three years, topping its total AI infrastructure spending over the past decade.
Benchmark&#8217;s Fawne Jiang hailed Alibaba as a leading player in <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43888574/alibabas-ai-expansion-e-commerce-growth-reinforce-bullish-analyst-outlook" rel="noreferrer noopener">China&#8217;s AI sector</a>, backed by a competitive edge in infrastructure, proprietary models, and application capacity across diverse use cases.
Price Action:&nbsp;BABA stock is down 4.61% at $130.42 premarket at&nbsp;the last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43920072/taiwan-semiconductor-poised-for-surge-goldman-sachs-predicts-rising-demand-for-taipei-traded-shares" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Poised For Surge, Goldman Sachs Predicts Rising Demand For Taipei-Traded Stock: Report</a></li>
</ul>
Photo courtesy Shutterstock

Asia

Emerging Markets

Tech

Media

BABA

Alibaba Expands AI Intern Workforce While DeepSeek Slashes Model Prices in Market Battle

B of A Securities analyst Kevin Fischbeck maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Buy and lowers the price target from $50 to $44.5.

ACHC

B of A Securities Maintains Buy on Acadia Healthcare Co, Lowers Price Target to $44.5

The companies are expected to integrate Juniper's Mist AI and IBM watsonx with the aim to address the complexities of managing IT networks that can help improve user experiences and lower operational costs.
The latest collaboration will focus on bringing Mist AI, a key part of Juniper's AI-Native Networking Platform that uses AI to optimize the E2E client-to-cloud experience across wireless, wired, SD-WAN, data center and security experiences, with IBM watsonx, IBM's portfolio of AI products designed to accelerate the impact of generative AI and drive productivity in core enterprise workflows.

JNPR

Juniper Networks, IBM Plan To Expand Collaboration Around Joint Sales, Marketing And Product Integration Efforts

B of A Securities analyst Jason Gerberry maintains Viatris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) with a Underperform and lowers the price target from $11 to $10.

VTRS

B of A Securities Maintains Underperform on Viatris, Lowers Price Target to $10

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and lowers the price target from $108 to $98.

USPH

Barrington Research Maintains Outperform on US Physical Therapy, Lowers Price Target to $98

Deepwater&#8217;s&nbsp;Gene Munster, shared his views on Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) recent performance, suggesting it was solid but fell short of extraordinary expectations. However, he remains upbeat on the stock.
What Happened:&nbsp;In an interview with Bloomberg on Thursday, Munster stated, &#8220;Yeah, I would actually say&nbsp;it was great, but not&nbsp;extraordinary. And that&#8217;s&nbsp;really what this needs to&nbsp;be.&#8221; He further elaborated on the company&#8217;s margin guidance and the impact of tariffs on its future performance.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Nvidia Stock Is a Buy on the Pullback, Deepwater&#039;s Munster Says" width="500" height="281" src="https://www.youtube.com/embed/ik-RnvblbLQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Munster further stated that the company raised guidance by $1 billion instead of a couple of billion, and margin guidance came in slightly lower than anticipated. Munster mentioned that when the company was asked if they could ramp up the margin amid the intense tariff situation in their conference call, their answer was ambiguous. The CFO stated &#8216;..it&#8217;s a little bit of an unknown until we understand what the U.S. government&#8217;s plan is.&#8221; This, Munster feels, could have dented investor confidence, leading to a decline in the stock in the after hours trading session on Wednesday.
He noted that Nvidia previously stated Blackwell chips would be sold out for &#8220;several quarters&#8221; in 2025, but this time there was no clarity over it, raising investor concerns.
SEE ALSO: <a href="https://www.benzinga.com/news/25/02/44036158/elon-musk-calls-on-retired-employees-to-return-to-work-at-faa-there-is-a-shortage-of-top-notch-air-traffic-controllers#google_vignette">Elon Musk Calls On Retired Employees To Return To Work At FAA: &#8216;There Is A Shortage Of Top Notch Air Traffic Controllers&#8217;</a>
Why It Matters: Despite these concerns, Munster remained optimistic about Nvidia&#8217;s long-term prospects. According to him, demand for advanced computing is at an all-time high, with new AI models requiring exponentially more processing power.
In his investor note, Munster stated, &#8221;&nbsp;I believe Jensen (Jensen Huang) is on the right track in claiming that reasoning increasingly drives a 100x increase in demand for compute. If true, the company will return to reporting impressive upside in CY26.&#8221; 
&#8220;Despite the emergence of cheaper alternatives to Nvidia GPUs including custom silicon, I believe they will remain the dominant workhorse for the next 3-5 years,&#8221; sums up Munster.
He believes the current dip presents a buying opportunity. &#8220;I think that this is a buy here on the pullback,&#8221; Munster told during the Bloomberg interview.
On the other hand, DA Davidson&#8216;s tech analyst, Gil Luria, predicted a <a href="https://www.benzinga.com/25/02/44034855/this-is-as-good-as-it-gets-for-nvidia-says-this-analyst-as-he-predicts-a-slowdown-for-the-chipmaker">slowdown in growth for Nvidia</a>. While the company&#8217;s fiscal year 2025 revenue more than doubled year-over-year to $130.5 billion, Luria suggested that this might be as good as it gets for Nvidia.
<ul>
<li>READ MORE:<a href="https://www.benzinga.com/tech/25/02/44037023/tesla-cybertruck-inventory-swells-despite-discounts-falling-short-of-elon-musks-vision"> Tesla Cybertruck Inventory Swells Despite Discounts, Falling Short of Elon Musk&#8217;s Vision</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

NVDA

Nvidia Stock Is A 'Buy On The Pullback, Says Top Analyst, Considers Earnings As 'Great But Not Extraordinary'

HC Wainwright &amp; Co. analyst Andrew Fein maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and lowers the price target from $55 to $46.

HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $46

Press Releases

VINCI PARTNERS TO ANNOUNCE SECOND QUARTER 2024 RESULTS AND HOST WEBCAST AFTER MARKET CLOSE ON WEDNESDAY, AUGUST 07, 2024

Dividends

VINCI PARTNERS REPORTS SECOND QUARTER 2024 EARNINGS RESULTS

VINCI PARTNERS TO ANNOUNCE THIRD QUARTER 2024 RESULTS AND HOST WEBCAST AFTER MARKET CLOSE ON THURSDAY, NOVEMBER 07, 2024

Real Estate

VINCI PARTNERS COMPLETES COMBINATION WITH COMPASS

VINCI PARTNERS ANNOUNCES LAUNCH OF NEW FORESTRY STRATEGY WITH THE ACQUISITION OF LACAN

VINCI PARTNERS REPORTS THIRD QUARTER 2024 EARNINGS RESULTS

VINCI PARTNERS TO HOST VIRTUAL WEBCAST TO DISCUSS COMBINATION WITH COMPASS ON NOVEMBER 25TH AT 8:00AM ET

Fintech

VINCI COMPASS TO HOST VIRTUAL WEBCAST TO DISCUSS COMBINATION TODAY AT 8:00AM ET

VINCI COMPASS TO ANNOUNCE FOURTH QUARTER 2024 RESULTS AND HOST CONFERENCE CALL AFTER MARKET CLOSE ON WEDNESDAY, FEBRUARY 26, 2025

VINCI COMPASS REPORTS FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RESULTS

Acadian Asset Management Inc. Common Stock

Acadian Asset Management

Associated Capital Group, Inc. Common Stock

Associated Cap Gr

AlTi Global

Bridge Investment Group Holdings Inc. Class A Common Stock

Bridge Investment Group

Crescent Capital BDC, Inc. - Common Stock

Crescent Capital BDC

Carlyle Secured Lending, Inc. - Closed End Fund

Carlyle Secured Lending

CION Invt

Diamond Hill Investment Group, Inc. - Class A Common Stock

Diamond Hill Investment

Fidus Investment Corporation - Closed End Fund

Fidus Investment

Gladstone Investment Corporation - Business Development Company

Gladstone Inv

GCM Grosvenor Inc. - Class A Common Stock

GCM Grosvenor

Gladstone Capital Corporation - Closed End Fund

Gladstone Cap

Horizon Technology Finance Corporation - Common Stock

Horizon Tech Finance

Innventure

MSC Income Fund

Nuveen Churchill Direct Lending Corp. Common Stock

Nuveen Churchill Direct

Noah Holdings Limited American Depositary Shares

Noah Holdings

PennantPark Floating Rate Capital Ltd. Common Stock

PennantPark Floating Rate

PennantPark Investment Corporation Common Stock

Pennant Park Investment

Palmer Square Capital BDC Inc. Common Stock

Palmer Square Capital BDC

Runway Growth Finance Corp. - Common Stock

Runway Gwth Fin

Saratoga Investment

Stellus Capital Investment Corporation Common Stock

Stellus Cap Investment

SLR Inv

BlackRock TCP Capital Corp. - Closed End Fund

Comments

Vinci Partners Inv

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga